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Abstract
Through the use of surrogate markers of efficacy, neoadjuvant
studies may facilitate the implementation of new treatments into
clinical practice. However, disease-free survival is the current
standard outcome endpoint for registration of a novel treatment.
The coupling of smaller neoadjuvant ‘proof of principle’ studies
with larger adjuvant registration trials offers the promise of
speeding up the time to market of new therapies. Clever new
designs, such as the ‘biological window’ and ‘learn on the way’,
can provide valuable insight regarding mechanisms of action and
resistance of these novel drugs by identifying patients who are
most likely to respond to a novel therapy early in the drug
development process. Using the ongoing neoadjuvant trials with
HER2 (human epidermal growth factor receptor 2)-directed
therapy as a paradigm, this article discusses recent innovations in
study design and the challenges of conducting translational
research in the neoadjuvant setting.
Introduction
Neoadjuvant chemotherapy is the standard of care for patients
with locally advanced and inflammatory breast cancer (IBC)
[1], with the goal of improving operability and eradicating
micrometastatic disease. In primary operable breast cancer,
neoadjuvant chemotherapy increases the rate of breast
conservation [2] and achieves similar overall survival (OS) as
adjuvant chemotherapy [3] without compromising local
control provided that careful multidisciplinary coordination is
planned from the outset [4]. Currently, the same regimens
used for adjuvant treatment are recommended for neo-
adjuvant therapy [5]. The initiation of chemotherapy prior to
surgery allows for the identification of two distinct prognostic
groups: patients able to attain a pathologic complete
response (pCR) with a favourable long-term outcome and
those with residual disease at surgery who are at a high risk
of relapse [6]. Unfortunately, there is no additional therapy
that has been shown to improve survival for patients failing to
achieve a pCR to an anthracycline-taxane regimen [7] and
this group of chemoresistant patients is desperately in need
of novel therapeutic options.
There are many unresolved clinical questions regarding the
use of neoadjuvant chemotherapy and additional locoregional
treatment [5,6]. Well-designed neoadjuvant studies can quickly
generate important preliminary data on the efficacy of novel
therapies based on short-term endpoints such as pCR. They
also offer an excellent opportunity to study the impact of
systemic therapies on breast cancer biology, to explore
surrogate markers of response (such as functional imaging),
and to select promising biomarkers for future validation
studies. The traditional model of conducting initial trials in
metastatic breast cancer patients with refractory disease
following standard therapy has been disappointing, as it
demands a lot of effort and requires a long time before the
drug reaches adjuvant registration. In addition, many new
agents thought to be successful at controlling minimal
residual disease have failed to demonstrate the efficacy for
patients with advanced disease. As a result, a new pathway
to accelerate the clinical development of emerging therapies
is sorely needed.
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The identification of the central role of the human epidermal
growth factor receptor 2 (HER2) protein in the pathogenesis
of HER2-overexpressing breast cancer is one of the greatest
successes of modern oncology. Over the last 10 years,
trastuzumab, a monoclonal antibody against the HER2
protein, has been approved for the treatment of HER2+
breast cancer, and a variety of exciting novel anti-HER2-
directed therapies that are entering clinical testing have been
developed. As such, HER2+ breast cancer represents the
ideal paradigm for a discussion of targeted neoadjuvant
breast cancer therapy. The purpose of this article is to review
ongoing neoadjuvant randomised clinical trials in HER2+ breast
cancer evaluating novel HER2-directed agents, with an
emphasis on recent innovations in trial design, platforms for the
evaluation of surrogate endpoints and translational research,
and the challenges in conducting neoadjuvant research.
Search strategy
Ongoing clinical trials were identified using the ClinicalTrials.gov
database on 22 May 2008 [8]. With the search terms
‘neoadjuvant breast cancer’ and ‘HER2 positive’, 29 studies
were recognised; with the terms ‘preoperative’ and ‘HER2
positive’, no additional studies were identified. The selection
was limited to neoadjuvant randomised clinical trials that
include HER2+ breast cancer. Trials investigating trastuzu-
mab as the only HER2 agent were excluded from the review
as we wished to focus on the neoadjuvant trials introducing
novel therapies for early breast cancer. With this strategy,
nine studies were identified and these are listed in Table 1
and Figure 1. Information regarding clinical trial design was
largely collected from the ClinicalTrials.gov library; additional
data (where available) were retrieved from the ClinicalTrials.gov
(PDQ®) database of the National Cancer Institute (Bethesda,
MD, USA) and through personal communication with the
principal investigators of individual studies.
Prior randomised neoadjuvant studies in
HER2+ disease
Even in the absence of targeted therapy against the HER2
signalling axis, HER2+ breast cancer demonstrates a higher
rate of pCR to traditional neoadjuvant chemotherapy [9]. A
retrospective single-series study suggests that patients with
HER2+ disease who experience a pCR to neoadjuvant
chemotherapy (without anti-HER2 therapies) may experience
a better disease-free survival (DFS) with long-term follow-up
[10]. Three randomised studies in the neoadjuvant setting
have evaluated the additional of trastuzumab to standard
therapy (Table 2). After 42 of a planned 165 patients had
been accrued, the M. D. Anderson study was initially stopped
because the pCR rate with trastuzumab added to paclitaxel
followed by 5-fluoruracil-epirubicin-cyclophosphamide (P→FEC)
chemotherapy was 65% versus 25% with chemotherapy
alone [11,12]. The larger NeOAdjuvant Herceptin (NOAH)
trial reported similar findings with trastuzumab added to
doxorubicin-paclitaxel followed by paclitaxel followed by
cyclophosphamide-methotrexate-5-fluoruracil (AP→P→CMF)
chemotherapy [13]. Interestingly, both of these studies
administered anthracycline chemotherapy concurrently with
trastuzumab and did not report a high rate of observed
cardiac toxicity. However, the 16% rate of clinical grade 3/4
congestive heart failure observed in the pivotal first-line
metastatic trial with concurrent trastuzumab and doxorubicin-
cyclophosphamide (AC) would suggest that this approach
should not be employed outside of a clinical trial setting [14].
More recently, the GeparQuattro study evaluating epirubicin,
cyclophosphamide, and docetaxel with or without
capecitabine and/or trastuzumab before surgery reported a
similar doubling in the observed pCR rate with the addition of
trastuzumab as seen in the NOAH study [15], using a more
conventional schedule of initiating trastuzumab after the
completion of anthracycline therapy.
Designs of the ongoing randomised
neoadjuvant studies in HER2+ disease
The majority of ongoing HER2-targeted trials are investigating
the efficacy of lapatinib in the neoadjuvant setting for HER2+
breast cancer (Table 1) [16-24]. Most of these studies use
pCR as a primary endpoint. pCR has been proven to
correlate with survival endpoints (DFS and OS) in neo-
adjuvant chemotherapeutic trials [25,26] but its precise
definition is still debated. Whereas early trials regarded pCR
as the absence of tumour on pathologic slides in breast and
axillary lymph nodes, some of the later trials defined pCR as
the absence of tumour in breast only without considering
nodal evaluation in the operative specimen. In addition,
definitions of pCR in neoadjuvant trials do not consistently
account for the presence of minimal residual cellularity and
residual in situ carcinoma. Recently, it was shown that the
extent of residual breast cancer burden, calculated as a
continuous index based on primary tumour measurements
(size and cellularity) and lymph node metastases (number and
size), correlates with survival outcomes [27]. Therefore, it is
clear that a unified definition of pathologic response for
neoadjuvant trials is required, much like the recent consensus
statement regarding standard efficacy endpoints (STEEP) for
adjuvant trials in early-stage disease [28]. Unfortunately, the
definitions of response endpoints in the ongoing neoadjuvant
trials with novel anti-HER2 agents are inconsistent (Table 1).
It should be noted that there is even less evidence regarding
the correlation between the extent of residual breast cancer
burden following neoadjuvant targeted therapy (with or
without chemotherapy) and survival [12,29].
At the present time, pCR is not robust enough to replace
survival as an endpoint for the registration of novel therapies.
Even though pCR appears to identify a subgroup with a
favourable prognosis [6,25,30], therapies that improve the
rate of pCR do not necessarily translate into long-term
differences in survival, as demonstrated by the addition of
taxane therapy in the NSABP (National Surgical Adjuvant
Breast and Bowel Project) B-27 trial [6]. However, the
evaluation of pCR in neoadjuvant studies can provide aAvailable online http://breast-cancer-research.com/content/11/1/201
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.critical early marker of efficacy, especially if a neoadjuvant
study is coupled with a larger adjuvant registration trial using
survival as its primary endpoint, such as in the case of the
ongoing neoALTTO (Neoadjuvant Lapatinib and/or Trastuzu-
mab Treatment Optimisation) and the ALTTO (Adjuvant
Lapatinib and/or Trastuzumab Treatment Optimisation) trials.
A similar model has been employed by the recently
completed neo-tAnGo and tAnGo trials in nonselected
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Figure 1
Trial design of ongoing randomised neoadjuvant studies targeting HER2 with new agents. *Only the randomization for HER2 positive patients is
presented. AC, doxorubicin-cyclophosphamide; EC, epirubicin-cyclophosphamide; FEC, 5-fluoruracil-epirubicin-cyclophosphamide;
H, trastuzumab; HER2, human epidermal growth factor receptor 2; L, lapatinib; letro, letrozole; NR, not reported; p, paclitaxel; R, randomisation,
T, docetaxel; X, capecitabine.populations [31]. Adjuvant registration trials require an
enormous financial and patient investment to detect small
differences in long-term outcome. A well-designed neoadju-
vant study can rapidly provide a ‘go/no go’ decision for an
emerging therapy. Invaluable data for the appropriate selec-
tion of patients and the evaluation of endpoints for a
subsequent adjuvant registration trial can be generated by a
well-designed neoadjuvant pilot trial: this concept is currently
being developed and explored by the Breast International
Group (Brussels, Belgium).
The proliferation marker Ki67 is another marker of interest to
be used as a surrogate marker for efficacy, especially with
endocrine therapy [17,32,33]. Declines in Ki67 after 2 weeks
of neoadjuvant treatment showed no difference between
tamoxifen and the combination of tamoxifen and anastrozole
in the IMPACT (Immediate Preoperative ‘Arimidex’ [anastro-
zole], Tamoxifen, or Arimidex Combined with Tamoxifen) trial,
while a significantly greater drop was found in the
anastrazole-alone arm [33], mirroring the DFS results of the
ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial
[34]. If these findings had been known before the launch of
the ATAC trial, the combination arm likely would have been
dropped from the study design from the outset, thereby
saving considerable financial and patient resources.
The eligibility criteria for the ongoing neoadjuvant anti-HER2
studies are similar. With the exception of the National Cancer
Institute study [35] that includes only patients with hormone
receptor-positive (HR+) and HER2+ breast cancer, all other
studies include HR+ and HR– disease. Although HR+ and
HR– HER2+ breast cancer may exhibit different clinical
behaviour [36], the joint inclusion of HER2+ disease regard-
less of HR status in the evaluation of novel anti-HER2 therapy
is justified, as trastuzumab has been shown to be effective
regardless of the expression of hormonal receptors [37].
Perhaps more controversial is the joint inclusion of IBC
together with locally advanced disease in the same study, as
IBC represents a separate entity with distinct epidemiology,
biology, and long-term outcome [38]. Although gene expres-
sion profiling (GEP) has identified the same five subtypes of
IBC as originally described for noninflammatory breast
cancer, differences in several key pathways and proteins do
exist [39]. IBC should be evaluated in separate clinical trials
or at least stratification should be planned at the time of
randomisation.
In contrast to the classical design, in which an experimental
therapy is compared with a standard therapy, examples of
novel designs are available amongst the ongoing anti-HER2
neoadjuvant studies: the so-called ‘biological window’ design
and ‘learn on the way’ design. The biological window design
exposes the patients to a short period of therapy with the
drug of interest alone to allow for the evaluation of biologic
endpoints. This design can also provide valuable insight
regarding drug pharmacodynamics and early evidence of
drug activity and highlight potential mechanisms of resis-
tance. As this phase of design is purely for research
purposes and does not offer patients direct therapeutic
benefit, there are ethical concerns that must be respected
[40]. A short biological window period can be followed by a
more classical design comparing standard neoadjuvant
therapy with new combinations, including targeted therapy
with curative intent, such as in the neoALTTO trial (Figure 2).
In the future, these studies may lead to a reduction in over-
treatment with chemotherapy, as they may identify patients
with excellent response to targeted therapy alone that can be
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Table 2
Reported randomised phase III trials with neoadjuvant trastuzumab
Number  pCR rate, percentage (95% CI)
of Patient  HER2 
Reference patients population Design assessment No H With H P value
Buzdar et al., 42 65%  T2  P  → FEC vs.  IHC 3+ or  26  65  NS
2005 [11],  40% N0/ P + H → FEC + H FISH+ (9-51) (43-84)
2007 [12] 57% N1
Gianni et al., 228 60%  T4  AP  → P → CMF vs.  IHC 3+ or  23  43  0.002
2007 [13] 85% N+ AP + H → P + H → FISH (NR) (NR)
CMF + H
Untch et al., 453 NA EC  → D or EC → NA 20 41  <0.001
2008 [15] DX or EC → D → (NR) (NR)
X vs. 
EC → D + H or EC 
→ DX + H or EC →
D + H → X + H
C, cyclophosphamide; CI, confidence interval; D, docetaxel; E, epirubicin; F, 5-fluoruracil; FISH, fluorescence in situ hybridization; H, trastuzumab;
HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; M, methotrexate; N, nodal status; NA, not applicable; NR, not
reported; NS, not significant; P, paclitaxel; pCR, pathologic complete response; T, tumour size; X, capecitabine.evaluated in a future chemotherapy-sparing study. Though
feasible, such neoadjuvant studies require careful planning,
enormous logistical support for material collection, and
efficient screening systems to identify appropriate patients, all
of which significantly increase the complexity and cost of
conducting such research.
The ‘learn on the way’ design uses information gained from
an initial treatment period to guide decisions regarding further
therapy. A patient who does not demonstrate early clinical
response at interim evaluation is unlikely to experience pCR
with completion of standard neoadjuvant chemotherapy
[41,42]. Thus, early-response evaluation can identify a sub-
group of patients with poor long-term outcome, providing the
opportunity to explore a switch to an alternative therapy to
improve the likelihood of pCR. To date, studies evaluating
neoadjuvant taxane [41] and capecitabine-vinca alkaloid [42]
combinations in nonselected populations have failed to
demonstrate a benefit for patients who do not respond to
anthracycline-based therapy. The GeparQuinto study
described in Figures 3-5 is an example of one such ‘learn on
the way’ approach [7]. The ‘learn on the way’ design is an
excellent opportunity to reduce overtreatment and validate
surrogate markers of response. Unfortunately, in the
GeparQuinto study, only the nonresponding HER2– cohort
will undergo a second randomisation based upon early
response, whereas in the HER2+ cohort early response is not
used to inform further decision-making. In the future, ‘learn on
the way’ designs based upon biomarker endpoints rather
than tumour shrinkage may be employed, although there are
important challenges regarding the standardisation of cutoff
values and interlaboratory reproducibility, along with the need
for prompt assessment must be addressed using such a
dynamic approach.
Translational research
The neoadjuvant setting is an ideal platform to evaluate the
predictive value of biomarkers using emerging technologies like
GEP, proteomics, functional imaging, circulating tumour cells
(CTCs), and the role of the host in the response to therapy
(pharmacodynamic and pharmacogenetic substudies) (Table 1).
Traditionally, translational research in breast cancer has been
characterised by efforts to validate single predictive biomarkers
using available tumour blocks from completed clinical trials, with
largely disappointing results. With new techniques like GEP and
biomarker models [43], several putative markers can be linked
together to obtain a more powerful prognostic or predictive tool.
The biological window design provides an especially valuable
opportunity for the rapid evaluation of pharmacodynamic
endpoints with biologic therapy.
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Figure 2
neoALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study design. CTCs, circulating tumour cells; FEC, 5-fluoruracil-
epirubicin-cyclophosphamide; PET, positron emission tomography. Note: In the combined Lapatinib + Trastuzumab + Paclitaxel arm, there is a
protocol amendment pending approval to reduce the Lapatinib dose to 750 mg/day because of concerns regarding excess diarrhea. Reprinted
with permission from GlaxoSmithKline and SOLTI (Spanish Breast Cancer Cooperative Group).Imaging modalities have not reliably been shown to predict
the response to neoadjuvant therapy. This is, in part, because
previous validation studies have been conducted in an
incomplete and piecemeal manner. Given the rapidly expan-
ding array of new imaging modalities, well-planned neo-
adjuvant studies with prospective integration of imaging
endpoints are required to define and compare the role of
molecular and functional imaging as early-response predic-
tors. In contrast to traditional imaging modalities based upon
anatomic evaluation of response, functional modalities such
as magnetic resonance imaging [44-47], magnetic resonance
spectroscopy [48], positron emission tomography [49,50],
single photon emission computed tomography [51], ultra-
sound with enhancement [52], and optical imaging [53] have
all shown the ability to predict early response and warrant
prospective evaluation in phase III clinical trials. In particular,
their ability to predict an early response using anti-HER2
therapy still needs to be demonstrated prospectively.
CTCs can be identified in the blood of 10% to 30% of
patients with early breast cancer and their detection is
associated with poor long-term DFS [54-56]. Currently, their
prognostic and predictive value is also being investigated in
neoadjuvant trials exploring the efficacy of novel anti-HER2
drugs (Table 1). Several methods of CTC detection have
been described, although reverse transcription-polymerase
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Figure 3
Decision tree from GeparQuinto study. B, bevacizumab; EC, epirubicin-
cyclophosphamide; H, trastuzumab; Her-2, human epidermal growth
factor receptor 2; L, lapatinib; Pw, paclitaxel weekly; T, docetaxel.
Reprinted with permission from GBG (German Breast Group).
Figure 4
GeparQuinto study design for HER2-negative cohort. B, bevacizumab
(15 mg/kg intravenously: day 1 q day 21 for eight cycles); C,
cyclophosphamide (600 mg/m2: day 1 q day 21 for four cycles); CR,
complete response; E, epirubicin (90 mg/m2: every 3 weeks for four
cycles); Her-2, human epidermal growth factor receptor 2; NC, no
change; PR, partial response; Pw, paclitaxel weekly (80 mg/m2: weekly
for 12 weeks total); Pw + R, paclitaxel weekly + RAD001 (5 mg daily);
R, randomisation; T, docetaxel (100 mg/m2: day 1 q day 21 for four
cycles). Reprinted with permission from GBG (German Breast Group).
Figure 5
GeparQuinto study design for HER2-positive cohort. C, cyclophosphamide (600 mg/m2: day 1 q day 21 for four cycles); E, epirubicin (90 mg/m2:
every 3 weeks for four cycles); H, trastuzumab (8 mg/kg: loading dose, 6 mg/kg: every 3 weeks); Her-2, human epidermal growth factor receptor 2;
L, lapatinib (1,250 mg daily for 24 weeks: run-in phase cycles 1 and 5: 1,000 mg daily); R, randomisation; T, docetaxel (100 mg/m2: every 3 weeks
for four cycles). Reprinted with permission from GBG (German Breast Group).chain reaction and immunomagnetic/fluorescent approaches
are the most advanced [57,58].
Studies exploring the efficacy of novel anti-HER2 drugs not
only are tumour-orientated but also will evaluate the role of
the host with prospective pharmacogenetic and pharmaco-
dynamic translational research studies. These studies will
provide us with valuable knowledge regarding interindividual
differences in drug metabolism and the efficacy of novel
agents [59,60].
Translational research rarely leads directly to the registration
of novel therapies, making it difficult to justify the high costs
of adequately powered translational research to industrial trial
sponsors [61]. However, innovative neoadjuvant translational
research may identify patients likely to benefit from novel
therapies that may ultimately reduce the number of partici-
pants needed for a subsequent registration study in the
adjuvant setting as well as increase the probability of
detecting a beneficial effect due to more accurate patient
selection. As the examples of trastuzumab for breast cancer
and gefitinib for lung cancer treatment illustrate, knowledge
of the appropriate patient population for a novel targeted
therapy can make the difference between a blockbuster drug
and a drug that never makes it to market [62-66].
Conclusions
Ongoing neoadjuvant studies exploring the efficacy of novel
anti-HER2 agents with innovative designs, like the ‘biological
window’ and ‘learn on the way’, promise to deliver new
knowledge of breast cancer biology and treatment. In the
future, a greater collaborative effort between research groups
is required to translate the new insights regarding the
molecular heterogeneity of breast cancer into individualised
therapies. Past failures have been marred by duplicative trial
designs, poorly planned translational research, and overesti-
mation of the benefit of experimental therapy in unselected
populations. A new partnership between academic investi-
gators, industry, patients, and policy-makers is needed, with a
common understanding that properly conducted innovative
neoadjuvant research can transform the dream of tailored
therapy for breast cancer into reality.
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